The Role of Tumor Volume Ratio in Predicting Clinically Significant Prostate Cancer on Transperineal Biopsy

被引:0
|
作者
Avolio, Pier Paolo [1 ,2 ]
Hassan, Toufic [1 ]
Addar, Abdulmalik [1 ]
Alshamsi, Hend [1 ]
Mcpherson, Victor [1 ]
Buffi, Nicolo Maria [2 ]
Lughezzani, Giovanni [2 ]
Loutochin, Oleg [1 ]
Rompre-Brodeur, Alexis [1 ]
Anidjar, Maurice [1 ]
Sanchez-Salas, Rafael [1 ]
机构
[1] McGill Univ, Hlth Ctr, Dept Surg, Div Urol, Montreal, PQ, Canada
[2] Human Univ, Dept Biomed Sci, Via R Levi Montalcini 4, I-20090 Milan, Italy
关键词
prostate cancer; magnetic resonance imaging; prostate biopsy; transperineal; tumor volume ratio; lesion volume; LESION VOLUME; GUIDELINES; DIAGNOSIS;
D O I
10.1089/end.2024.0428.fts24
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Multiparametric magnetic resonance imaging (mpMRI) has made dramatic inroads into the management of localized prostate cancer (PCa); however, not all suspicious lesions represent clinically significant (cs) PCa. We aimed to analyze the hypothetical effect of incorporating tumor volume ratio (TVR) into prostate biopsy (PBx) decision-making. Materials and Methods: Two hundred and fifty-two patients with suspicious lesions at mpMRI undergoing transperineal PBx under local anesthesia between 2019 and 2022 were retrospectively evaluated. TVR was calculated by dividing the tumor volume by the prostate volume. A regression model was used to assess predictors of csPCa. Descriptive statistics were applied to evaluate the effect of including TVR in PBx decision-making. Results: Overall, 119 patients (47%) were found to have csPCa. Age (p < 0.001), prior negative PBx (p = 0.011), and TVR (p < 0.001) were found to be independent predictors of csPCa. Applying the TVR cutoff of 0.23, a total of 117/252 (46%) PBx would have been avoided at the cost of missing csPCa in 26 (10%) men. Conclusions: Age, previous biopsy status, and TVR were found to be independent predictors of csPCa in men with suspicious lesions at mpMRI. Implementation of TVR into PBx decision-making improves the accuracy of mpMRI. Future studies are required to validate our findings and evaluate the role of TVR in avoiding unnecessary PBx.
引用
收藏
页码:S47 / S53
页数:7
相关论文
共 50 条
  • [31] Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer
    Morote, Juan
    Borque-Fernando, Angel
    Triquell, Marina
    Campistol, Miriam
    Servian, Pol
    Abascal, Jose M.
    Planas, Jacques
    Mendez, Olga
    Esteban, Luis M.
    Trilla, Enrique
    EUROPEAN UROLOGY OPEN SCIENCE, 2023, 53 : 46 - 54
  • [32] Is systematic sextant biopsy suitable for the detection of clinically significant prostate cancer?
    Manseck, A
    Froehner, M
    Oehlschlaeger, S
    Hakenberg, O
    Friedrich, K
    Theissig, F
    Wirth, MP
    UROLOGIA INTERNATIONALIS, 2000, 65 (02) : 80 - 83
  • [33] MRI Fusion-Targeted Transrectal Prostate Biopsy and the Role of Prostate-Specific Antigen Density and Prostate Health Index for the Detection of Clinically Significant Prostate Cancer in Southeast Asian Men
    Tan, Teck Wei
    Png, Keng Siang
    Lee, Chau Hung
    Yuwono, Arianto
    Yeow, Yuyi
    Chong, Kian Tai
    Lee, Yee Mun
    Tan, Cher Heng
    Tan, Yung Khan
    JOURNAL OF ENDOUROLOGY, 2017, 31 (11) : 1111 - 1116
  • [34] MultiParametric Magnetic Resonance Imaging-Based Nomogram for Predicting Prostate Cancer and Clinically Significant Prostate Cancer in Men Undergoing Repeat Prostate Biopsy
    Huang, Cong
    Song, Gang
    Wang, He
    Ji, Guangjie
    Li, Jie
    Chen, Yuke
    Fan, Yu
    Fang, Dong
    Xiong, Gengyan
    Xin, Zhongcheng
    Zhou, Liqun
    BIOMED RESEARCH INTERNATIONAL, 2018, 2018
  • [35] Initial transperineal prostate biopsy experience at a high-volume center
    Berkenwald, Aaron
    Stensland, Kristian D.
    Sebel, Luke E.
    Moinzadeh, Alireza
    Faust, William
    CANADIAN JOURNAL OF UROLOGY, 2021, 28 (03) : 10692 - 10698
  • [36] Role of Positive Biopsy Core Ratio in Prostate Cancer Patients
    Kano, Hiroshi
    Izumi, Kouji
    Nakagawa, Ryunosuke
    Toriumi, Ren
    Aoyama, Shuhei
    Kamijima, Taiki
    Shimada, Takafumi
    Naito, Renato
    Kadomoto, Suguru
    Iwamoto, Hiroaki
    Yaegashi, Hiroshi
    Kawaguchi, Shohei
    Nohara, Takahiro
    Shigehara, Kazuyoshi
    Kadono, Yoshifumi
    Mizokami, Atsushi
    ANTICANCER RESEARCH, 2023, 43 (10) : 4619 - 4626
  • [37] Predicting clinically significant prostate cancer with a deep learning approach: a multicentre retrospective study
    Zhao, Litao
    Bao, Jie
    Qiao, Xiaomeng
    Jin, Pengfei
    Ji, Yanting
    Li, Zhenkai
    Zhang, Ji
    Su, Yueting
    Ji, Libiao
    Shen, Junkang
    Zhang, Yueyue
    Niu, Lei
    Xie, Wanfang
    Hu, Chunhong
    Shen, Hailin
    Wang, Ximing
    Liu, Jiangang
    Tian, Jie
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (03) : 727 - 741
  • [38] Transperineal systematic biopsies in addition to targeted biopsies are important in the detection of clinically significant prostate cancer
    Lahoud, John
    Doan, Paul
    Kim, Lawrence H.
    Patel, Manish, I
    ANZ JOURNAL OF SURGERY, 2021, 91 (04) : 584 - 589
  • [39] Efficacy of Prostate Biopsies via Transperineal and Transrectal Routes for Significant Prostate Cancer Detection: A Multicenter Paired-Matched Study
    Paesano, Nahuel
    Picola, Natalia
    Munoz-Rodriguez, Jesus
    Ruiz-Plazas, Xavier
    Munoz-Rivero, Marta V.
    Celma, Ana
    Garcia-de Manuel, Gemma
    Miro, Berta
    Servian, Pol
    Abascal, Jose M.
    Trilla, Enrique
    Morote, Juan
    DIAGNOSTICS, 2025, 15 (03)
  • [40] Beyond blood biomarkers: the role of SelectMDX in clinically significant prostate cancer identification
    Ferro, Matteo
    Rocco, Bernardo
    Maggi, Martina
    Lucarelli, Giuseppe
    Falagario, Ugo Giovanni
    Del Giudice, Francesco
    Crocetto, Felice
    Barone, Biagio
    La Civita, Evelina
    Lasorsa, Francesco
    Brescia, Antonio
    Catellani, Michele
    Busetto, Gian Maria
    Tataru, Octavian Sabin
    Terracciano, Daniela
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2023, 23 (12) : 1061 - 1070